Entinostat (MS-275)

For research use only. Not for use in humans.

製品コードS1053 別名:SNDX-275

Entinostat (MS-275)化学構造

分子量(MW):376.41

Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Entinostat induces autophagy and apoptosis. Phase 3.

サイズ 価格(税別) 在庫  
10mM (1mL in DMSO) JPY 17100 あり
JPY 13600 あり
JPY 26900 あり
JPY 46800 あり
JPY 129800 あり
最寄りの販売代理店を探す

お探しのディーラーが見当たらない場合は直接こちらのメールアドレスまでお問い合わせください:[email protected]

バルク問合せ

文献中Selleckの製品使用例(282)

製品安全説明書

HDAC阻害剤の選択性比較

生物活性

製品説明 Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Entinostat induces autophagy and apoptosis. Phase 3.
ターゲット
HDAC1 [2]
(Cell-free assay)
HDAC3 [2]
(Cell-free assay)
0.51 μM 1.7 μM
体外試験

MS-275 shows inhibitory to HDACs by 2'-amino group. MS-275 induces accumulation of p21WAF1/CIP1 and gelsolin in K562 cell. MS-275 could reduce S-phase cells and induce G1-phase cells in A2780 cell. MS-275 inhibits the proliferation of human tumor cell lines including A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 with IC50 from 41.5 nM to 4.71 μM, which due to HAD-inhibition. [1] MS-275 is not sensitive to other HDACs (4, 6, 8 and 10) with IC50 about/above 100 μM. [2] MS-275 shows great inhibition to human leukemia and lymphoma cells, including U937, HL-60, K562, and Jurkat. MS-275 also decreases expression of cyclin D1 and the antiapoptotic proteins Mcl-1 and XIAP. [3]

細胞データ
Cell Lines Assay Type Concentration Incubation Time Formulation Activity Description PMID
SCC-3 NH20V5NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2TOcGlEPTB;MD6wOlEh|ryP MVTTRW5ITVJ?
ALL-PO MkfXS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGnYTZpKSzVyPUCuNFY{PTVizszN MYnTRW5ITVJ?
697 MWLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlXCTWM2OD1yLkC5PVc3KM7:TR?= NVGzNolwW0GQR1XS
NCI-H748 NYPkPZJ1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVLJR|UxRTBwMUCzN|Qh|ryP M4\aOXNCVkeHUh?=
NKM-1 NHfuNXpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MWjJR|UxRTBwMUC5NVIh|ryP NX;DTHZZW0GQR1XS
ES1 NXXieI9lT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NX;1[5R4UUN3ME2wMlEyOjV3IN88US=> Mlr1V2FPT0WU
NCI-H1963 M2XQWWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M1zOe2lEPTB;MD6xNVU4QSEQvF2= M4P5NXNCVkeHUh?=
NCI-H1417 M{HlbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mo\STWM2OD1yLkGyPVc1KM7:TR?= NI\UcHpUSU6JRWK=
NEC8 M2PHcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MXHJR|UxRTBwMUO1Nlch|ryP NH31Vo9USU6JRWK=
CRO-AP2 MlWwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NILaeZJKSzVyPUCuNVY5QDlizszN M1P1eXNCVkeHUh?=
A3-KAW NI\zVZdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIjLOIJKSzVyPUCuNVc3OjdizszN M4\zdHNCVkeHUh?=
SF539 NYrZVpgyT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1vXSmlEPTB;MD6xPVU6OyEQvF2= MYLTRW5ITVJ?
NOS-1 M2HWT2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3PPSGlEPTB;MD6xPVYyQSEQvF2= NF70cYhUSU6JRWK=
NTERA-S-cl-D1 NXPlSFJsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NWn5OoxsUUN3ME2wMlIxOTF|IN88US=> NV64VllpW0GQR1XS
COR-L88 NUS5R2R7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3;yd2lEPTB;MD6yNlk2QSEQvF2= MX3TRW5ITVJ?
EM-2 NWXMUG5VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{TkbWlEPTB;MD6yOFA4QSEQvF2= MkPNV2FPT0WU
KARPAS-45 M1e5SGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MoWzTWM2OD1yLkK3PFM{KM7:TR?= NHG0RZlUSU6JRWK=
DSH1 NHLDdoNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M{[0N2lEPTB;MD6yPFcxQCEQvF2= MnvPV2FPT0WU
HT-144 M1:xdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGPpSlVKSzVyPUCuN|AzPTZizszN M{G0bXNCVkeHUh?=
ATN-1 M3ez[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkPGTWM2OD1yLkOwOVc3KM7:TR?= NXGwc|JOW0GQR1XS
HEL NXjSTmJoT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MV7JR|UxRTBwM{GzOFgh|ryP MUnTRW5ITVJ?
NB12 NF\nRlhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M1fmNGlEPTB;MD6zNVc2PiEQvF2= NIfVRpdUSU6JRWK=
LU-139 MnjJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYnJR|UxRTBwM{O1NUDPxE1? MlLxV2FPT0WU
J-RT3-T3-5 MlnyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NUC1ZndwUUN3ME2wMlM{PzF4IN88US=> NUPhUmdtW0GQR1XS
MOLT-13 M4fBdmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlL5TWM2OD1yLkOzPFEh|ryP Mk\PV2FPT0WU
SR MlrDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M33HbGlEPTB;MD6zOFI3OSEQvF2= Ml7wV2FPT0WU
CMK MYfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWPXSItnUUN3ME2wMlM2PzJ5IN88US=> MX\TRW5ITVJ?
ES8 M1;Ebmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTBwM{[wNlIh|ryP NWnNWlVSW0GQR1XS
LB647-SCLC M1TRd2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\hToRzUUN3ME2wMlM3PzNizszN MmPLV2FPT0WU
TE-8 NIG5d|RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3XD[GlEPTB;MD6zOlk{PSEQvF2= MmW1V2FPT0WU
BV-173 MkK5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{fkWmlEPTB;MD6zO|EzOSEQvF2= MkTvV2FPT0WU
DEL MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M13r[WlEPTB;MD6zO|Q5PyEQvF2= M3rwVXNCVkeHUh?=
ARH-77 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2PYR2lEPTB;MD6zPFE6OyEQvF2= M4i2NXNCVkeHUh?=
NCCIT MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{DNfWlEPTB;MD6zPFY1QSEQvF2= NWr1bmRsW0GQR1XS
RPMI-8402 NVjSS4VvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHHiV5dKSzVyPUCuN|g4ODFizszN NIXhepZUSU6JRWK=
MONO-MAC-6 MnzHS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4fsWmlEPTB;MD6zPFc4PiEQvF2= MnrMV2FPT0WU
SK-MM-2 MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Ml\wTWM2OD1yLkO5PFY5KM7:TR?= M3HuT3NCVkeHUh?=
CHP-126 MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NU\zcoNoUUN3ME2wMlQxOjNzIN88US=> NWXjdI1OW0GQR1XS
A101D MlnJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGTZXoZKSzVyPUCuOFA{KM7:TR?= MVrTRW5ITVJ?
SCH MnTvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2Dl[WlEPTB;MD60NFM1OiEQvF2= NFnBOYRUSU6JRWK=
NMC-G1 MlrrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NEXkVoJKSzVyPUCuOFA{PjdizszN MUPTRW5ITVJ?
NCI-H209 M3;1TGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NEnSPFRKSzVyPUCuOFA3OTNizszN M1PJTHNCVkeHUh?=
MOLT-16 NH3pe|FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M2G1O2lEPTB;MD60NVAyPyEQvF2= MmLWV2FPT0WU
RPMI-6666 NVvJTGRlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NUPyZYNPUUN3ME2wMlQyOTJizszN NUewUlJiW0GQR1XS
OPM-2 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NYHFOlh{UUN3ME2wMlQyPTF|IN88US=> MmXTV2FPT0WU
MRK-nu-1 MknZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVnJR|UxRTBwNEOxOVMh|ryP Ml3JV2FPT0WU
BC-1 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3\FcWlEPTB;MD60N|QxOyEQvF2= NHr5OYJUSU6JRWK=
MHH-NB-11 NVTwUpNbT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHzv[XdKSzVyPUCuOFM1PTNizszN NVq1ToZrW0GQR1XS
Ramos-2G6-4C10 MYDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1SwNmlEPTB;MD60N|g6PyEQvF2= NHXqTVJUSU6JRWK=
LS-513 M17jVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTBwNES1NFEh|ryP M4PIT3NCVkeHUh?=
K5 M{HVNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVHJR|UxRTBwNEewNlUh|ryP M{jCb3NCVkeHUh?=
HOP-62 M4HOVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXDW5E6UUN3ME2wMlQ5OzV6IN88US=> NG\p[YFUSU6JRWK=
NCI-H187 NGD5fo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVLJR|UxRTBwNEmyNlch|ryP MVLTRW5ITVJ?
BE-13 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFO4eVdKSzVyPUCuOFk3PjFizszN M4T3eHNCVkeHUh?=
HC-1 MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoDLTWM2OD1yLkWwOFc{KM7:TR?= M37TbHNCVkeHUh?=
ACN NFfBfVRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MX\JR|UxRTBwNUGwNlgh|ryP MVPTRW5ITVJ?
HCC1599 NF\XW29Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnPUTWM2OD1yLkWxOVch|ryP MYTTRW5ITVJ?
MV-4-11 MUnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2nKXWlEPTB;MD61N|A1OSEQvF2= MXnTRW5ITVJ?
LC-2-ad MkK1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4LENmlEPTB;MD61N|Y3OyEQvF2= MYPTRW5ITVJ?
HL-60 M1;JeGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 Mn3PTWM2OD1yLkW0NlYyKM7:TR?= NGXWTXJUSU6JRWK=
NB17 NYrsTmFtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{\tRWlEPTB;MD61OFM5KM7:TR?= NFvmRYlUSU6JRWK=
TE-1 NF3SV2hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4rRSWlEPTB;MD61OVMxPiEQvF2= Mm\PV2FPT0WU
NCI-H524 M4XISGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{DBPWlEPTB;MD61OVQxOSEQvF2= M{f0enNCVkeHUh?=
MZ7-mel M{fONWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFrWWYJKSzVyPUCuOVYyODVizszN NVvwcoRQW0GQR1XS
L-363 NX3I[3VlT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnXETWM2OD1yLkW2OlU4KM7:TR?= M1rxSXNCVkeHUh?=
BL-41 M1G3fGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXGyd5hwUUN3ME2wMlU3QDh7IN88US=> NVHuco82W0GQR1XS
LU-134-A NXnVOW5NT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NGfpcIhKSzVyPUCuOVcxPzNizszN NFTSXZpUSU6JRWK=
SIG-M5 NX:5S21KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3myU2lEPTB;MD61O|g1QCEQvF2= NIj0enVUSU6JRWK=
ONS-76 MmrYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NGfpRYJKSzVyPUCuOVgzPDJizszN MoXRV2FPT0WU
KARPAS-299 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NVe5VnBJUUN3ME2wMlU5PTB2IN88US=> MWPTRW5ITVJ?
DU-4475 M2PCXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M172eWlEPTB;MD61PFcxOyEQvF2= MknzV2FPT0WU
NB69 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4TYbmlEPTB;MD61PVgzPSEQvF2= M2T3WXNCVkeHUh?=
MHH-PREB-1 NVywUVlQT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHfkWZlKSzVyPUCuOlA4OTlizszN MorJV2FPT0WU
LU-165 NWrhe49oT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnTCTWM2OD1yLk[xPFEzKM7:TR?= MXfTRW5ITVJ?
LOUCY NY\rNndNT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3LZfGlEPTB;MD62N|M3PCEQvF2= MnTiV2FPT0WU
NCI-H526 NYr3c4p1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MWjJR|UxRTBwNkO1OFEh|ryP NXfkVnFWW0GQR1XS
KE-37 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MVPJR|UxRTBwNkSyO|Yh|ryP M{\yXnNCVkeHUh?=
NALM-6 Ml3BS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NVrF[Yo4UUN3ME2wMlY1QDZizszN M2TpPHNCVkeHUh?=
CW-2 NYfKSYRkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NVniS3RiUUN3ME2wMlY2Pzl2IN88US=> MYXTRW5ITVJ?
SU-DHL-1 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3P5XGlEPTB;MD62OVk1PyEQvF2= NYXoW3lpW0GQR1XS
NB13 NEnOeHFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmDXTWM2OD1yLk[2PFE4KM7:TR?= NEDSS4pUSU6JRWK=
QIMR-WIL M1ewfWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYLkXGJHUUN3ME2wMlY5OzR|IN88US=> MnvCV2FPT0WU
ECC12 NWrUd|hJT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHnHRWxKSzVyPUCuO|AxQDZizszN M3LPUXNCVkeHUh?=
KALS-1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NEj0OphKSzVyPUCuO|A1QTJizszN MXfTRW5ITVJ?
COR-L279 MoP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M{j4W2lEPTB;MD63NFk6PiEQvF2= NFu5NHJUSU6JRWK=
NB14 MkHwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWXtTHU{UUN3ME2wMlczPjF5IN88US=> M37RdHNCVkeHUh?=
CCRF-CEM MX7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWjJR|UxRTBwN{S2OlEh|ryP NWq0UJI4W0GQR1XS
SW954 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmGxTWM2OD1yLke1PVk6KM7:TR?= NFP1[|lUSU6JRWK=
IST-SL1 Ml24S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFS1TnFKSzVyPUCuO|c{PDhizszN Mn;tV2FPT0WU
LAMA-84 NXPjOY5VT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MmW2TWM2OD1yLke3OVY4KM7:TR?= NVTRc4k{W0GQR1XS
Daudi MorDS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlnnTWM2OD1yLke3OlgyKM7:TR?= MkTJV2FPT0WU
BC-3 MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NV\qTG1[UUN3ME2wMlc5OzB6IN88US=> MUXTRW5ITVJ?
HCC2998 MnnTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? Mkn4TWM2OD1yLke4N|Yh|ryP MnvnV2FPT0WU
NCI-H69 M2ftb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4D6N2lEPTB;MD64NFE1PyEQvF2= M4i4OHNCVkeHUh?=
CPC-N NWTHN3FCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkDmTWM2OD1yLkiwOVI1KM7:TR?= NVTDSId3W0GQR1XS
NOMO-1 NFH5UpZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWHMepREUUN3ME2wMlgyODh2IN88US=> MYPTRW5ITVJ?
CESS NYqxV2xvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MYPJR|UxRTBwOEGxPVch|ryP NE\DdnhUSU6JRWK=
LC4-1 MmfvS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MYLJR|UxRTBwOESwNFch|ryP MXrTRW5ITVJ?
BL-70 NITDfJpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\HbGlEPTB;MD64OVcxOiEQvF2= M3f6c3NCVkeHUh?=
ES4 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFfwXXlKSzVyPUCuPFU5PjhizszN M2fHT3NCVkeHUh?=
HCE-T NVryN4g1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MVjJR|UxRTBwOEexO|Eh|ryP M2LROHNCVkeHUh?=
JAR MmrUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NYjWNlBmUUN3ME2wMlg4QDJ5IN88US=> M{HF[HNCVkeHUh?=
ST486 NUXGNZlvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MlfSTWM2OD1yLki3PVE4KM7:TR?= M4fQXnNCVkeHUh?=
KS-1 NGH6OmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NVzSXJVQUUN3ME2wMlg5ODl4IN88US=> NF3QcnRUSU6JRWK=
GDM-1 NFG3PHNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnTdZRpUUN3ME2wMlg5Pjh5IN88US=> NUfqN5Y4W0GQR1XS
EHEB MXHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoPFTWM2OD1yLkmyOVg2KM7:TR?= M3L5TnNCVkeHUh?=
LB2518-MEL NVXQfVQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M4LvdGlEPTB;MD65N|I5PCEQvF2= MoTRV2FPT0WU
GOTO M4fPW2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{jXXWlEPTB;MD65OVA4PiEQvF2= MX7TRW5ITVJ?
LXF-289 NELicW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NG\5fFBKSzVyPUCuPVU6ODFizszN MmLTV2FPT0WU
ES6 NWPVNGUxT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Mnv1TWM2OD1yLkm2OFM4KM7:TR?= MkPlV2FPT0WU
OS-RC-2 MnfKS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1nIVWlEPTB;MD65Olg{KM7:TR?= M3WwTHNCVkeHUh?=
DMS-153 NIT5cVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTBwOUe0Olkh|ryP MnHYV2FPT0WU
SK-PN-DW Ml\1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NXnnbWNEUUN3ME2wMlk4QDNzIN88US=> MnnMV2FPT0WU
HH M2P5[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NG\JVnVKSzVyPUCuPVg6PTlizszN NYLBbXBmW0GQR1XS
SH-4 M3TkfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2PPSWlEPTB;MT6wNlQyKM7:TR?= NEK5O3hUSU6JRWK=
MOLT-4 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NE\uW5VKSzVyPUGuNFM1PTRizszN M1:xPXNCVkeHUh?=
TGW NFXObo9Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTFwMEe2O|Uh|ryP M2rwOHNCVkeHUh?=
L-540 M4LROWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MorQTWM2OD1zLkGwOlA1KM7:TR?= NHrMW|BUSU6JRWK=
PF-382 MWPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUDJR|UxRTFwMUG1NVMh|ryP M2jLcXNCVkeHUh?=
LC-1F M{OxR2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3rOb2lEPTB;MT6xNlAxPyEQvF2= M3LMTHNCVkeHUh?=
OVCAR-4 MoH4S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlXXTWM2OD1zLkGzNVY2KM7:TR?= NWTXNoU6W0GQR1XS
A4-Fuk M2Dqb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NU\1WldSUUN3ME2xMlE2OzZ2IN88US=> NWP1d3dUW0GQR1XS
HCC2218 M3vRVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3fRN2lEPTB;MT6xOlY1OSEQvF2= MoXZV2FPT0WU
HAL-01 M3\hb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MWDJR|UxRTFwMU[5OFMh|ryP NF20T4ZUSU6JRWK=
IST-MEL1 NUizUYZLT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYS0cZF6UUN3ME2xMlE4PjV7IN88US=> NHvoXHJUSU6JRWK=
NCI-H719 Mlq1S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MlzvTWM2OD1zLkG3PFk5KM7:TR?= M4rxVXNCVkeHUh?=
EVSA-T MV\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NF3kTHlKSzVyPUGuNVgyOTRizszN M4fpN3NCVkeHUh?=
SK-NEP-1 M{Xh[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUTmZ2h{UUN3ME2xMlIxOjZ4IN88US=> MkDOV2FPT0WU
OCUB-M NF\lNIRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWfLXYNxUUN3ME2xMlIyPDh7IN88US=> M4jvUHNCVkeHUh?=
MEG-01 MlzuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIj5NpRKSzVyPUGuNlIyOThizszN NGTjb5NUSU6JRWK=
no-10 NYrIO4VUT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NU\UW2NPUUN3ME2xMlI{OTF{IN88US=> MUnTRW5ITVJ?
MHH-CALL-2 MnrUS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWDJR|UxRTFwMkS3NlEh|ryP MkDDV2FPT0WU
SK-N-DZ NHX4OZZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXXleXhQUUN3ME2xMlI1Pzd4IN88US=> NGm0OIdUSU6JRWK=
SCLC-21H MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUPJR|UxRTFwMk[0O|gh|ryP MVTTRW5ITVJ?
CTV-1 NWHvOJBCT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MY\JR|UxRTFwMke0NlUh|ryP M1v5[HNCVkeHUh?=
NB1 MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUnVSXdkUUN3ME2xMlI4PzN{IN88US=> MUDTRW5ITVJ?
NCI-H64 MlKyS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NW\ObGFSUUN3ME2xMlI5PDZ{IN88US=> MXzTRW5ITVJ?
MDA-MB-134-VI NHjkelNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NH;iZpRKSzVyPUGuNlg2PzdizszN MVjTRW5ITVJ?
LB2241-RCC NUK3[oZkT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3fadmlEPTB;MT6yPFY3OyEQvF2= M17RdHNCVkeHUh?=
8-MG-BA MnvZS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVrJR|UxRTFwMki4OlYh|ryP NHjPbotUSU6JRWK=
LP-1 MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGT4WotKSzVyPUGuNlk6PDdizszN NVPqT5QzW0GQR1XS
LS-411N NWm4e5ozT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXzJR|UxRTFwM{C5PVgh|ryP NFftSZhUSU6JRWK=
CAL-148 M33sTGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NUXObndSUUN3ME2xMlMzPTR{IN88US=> M32ycXNCVkeHUh?=
NCI-H2171 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NUfhdZh2UUN3ME2xMlM1PTB{IN88US=> Ml\uV2FPT0WU
JiyoyeP-2003 M{\lZWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnnTTWM2OD1zLkO1N|kh|ryP NVmzUYZxW0GQR1XS
NCI-H2107 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3jBSGlEPTB;MT6zOVg5OyEQvF2= Mle4V2FPT0WU
BB30-HNC MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmDPTWM2OD1zLkO4PVc5KM7:TR?= MUfTRW5ITVJ?
K-562 MWfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mmn3TWM2OD1zLkO5NlE6KM7:TR?= MVvTRW5ITVJ?
PSN1 MmXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTFwNEKyPFch|ryP NVrsVJZ[W0GQR1XS
HCC2157 NFX2PYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mor0TWM2OD1zLkSyOlkyKM7:TR?= MnzDV2FPT0WU
SBC-1 NH3mVlVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGrPfnpKSzVyPUGuOFI4PDFizszN M1nDbHNCVkeHUh?=
MC116 NEPqOZNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmXOTWM2OD1zLkSzOlE2KM7:TR?= NH;hPWxUSU6JRWK=
KARPAS-422 M{nLfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGfLWW1KSzVyPUGuOFU{PThizszN MYrTRW5ITVJ?
LB996-RCC NWC2WnNOT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NV:wNI9OUUN3ME2xMlQ4OTB|IN88US=> MlziV2FPT0WU
MSTO-211H M1vNS2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIHlUlZKSzVyPUGuOFc6QDdizszN NH;5XlZUSU6JRWK=
BT-474 NYHxdFR7T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NHvwU|hKSzVyPUGuOVE4PjRizszN M{PScXNCVkeHUh?=
A388 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3SyTGlEPTB;MT61NVk1PSEQvF2= NHLXUWpUSU6JRWK=
SJSA-1 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGDOO4pKSzVyPUGuOVIzPiEQvF2= NF;rcINUSU6JRWK=
COLO-829 NEO0PWZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmG5TWM2OD1zLkWzOVY1KM7:TR?= MkfhV2FPT0WU
KM-H2 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MYLJR|UxRTFwNU[2O{DPxE1? MW\TRW5ITVJ?
GR-ST NXr1fZdKT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3rIVmlEPTB;MT61OlgzKM7:TR?= M1LDPHNCVkeHUh?=
RPMI-8866 NWnVVFVsT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MXfJR|UxRTFwNkCxOFQh|ryP M1ricXNCVkeHUh?=
KG-1 NEHwc3hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnvkTWM2OD1zLk[xPVAyKM7:TR?= MnrUV2FPT0WU
NCI-H82 MXnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NWfkbVJDUUN3ME2xMlY{PDB4IN88US=> MX;TRW5ITVJ?
LB1047-RCC MmrCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1HmRmlEPTB;MT62N|Q2QSEQvF2= MnGwV2FPT0WU
KM12 M4\mcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MUPJR|UxRTFwNkS3JO69VQ>? NYDHZlRQW0GQR1XS
NB5 MmDiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1\NXmlEPTB;MT62OVY4PyEQvF2= NFzVVGpUSU6JRWK=
HDLM-2 MYnHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX65VXI2UUN3ME2xMlY5OjhzIN88US=> MXPTRW5ITVJ?
KU812 MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXfEXWNzUUN3ME2xMlY6PjB3IN88US=> NYP2TZJGW0GQR1XS
DB MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2\KZmlEPTB;MT63NFM2OyEQvF2= M4W4SHNCVkeHUh?=
HD-MY-Z Ml\qS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MVTJR|UxRTFwN{WyN|Qh|ryP NHXIfYtUSU6JRWK=
KURAMOCHI MkfLS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MULJR|UxRTFwN{eyNFch|ryP M4WxN3NCVkeHUh?=
ETK-1 NVqxWFRjT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NIHWN3FKSzVyPUGuO|g5PzlizszN M4joV3NCVkeHUh?=
SK-UT-1 M2XVfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NFjue2VKSzVyPUGuO|k{QDhizszN MYTTRW5ITVJ?
HUTU-80 NFO0O3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MnjaTWM2OD1zLke5OVA5KM7:TR?= M4O0cHNCVkeHUh?=
ES7 MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MXvJR|UxRTFwOECzNFIh|ryP Mm\SV2FPT0WU
SW872 M3;VcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlzNTWM2OD1zLkixN|k2KM7:TR?= MUnTRW5ITVJ?
TK10 M13zOWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYrJR|UxRTFwOEOxNFgh|ryP NGTWbmpUSU6JRWK=
LB831-BLC MX;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? Mo\3TWM2OD1zLkizOVY{KM7:TR?= MX7TRW5ITVJ?
TE-9 M2K5bWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NGWzOZdKSzVyPUGuPFQ1OjJizszN MoD2V2FPT0WU
MLMA MXPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1PoXWlEPTB;MT64PFI{PCEQvF2= M17tUXNCVkeHUh?=
D-542MG NFnRSI5Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MmrBTWM2OD1zLki5N|c{KM7:TR?= NWXubGkyW0GQR1XS
EW-16 NYrxT2ZIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{faZmlEPTB;MT65NlczKM7:TR?= MmfSV2FPT0WU
LOXIMVI M{XrTWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M3zzVWlEPTB;MT65N|I5KM7:TR?= NUTMeJZSW0GQR1XS
GB-1 MmOwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFTXNnZKSzVyPUGuPVM5PjZizszN M33BXHNCVkeHUh?=
IST-SL2 MlThS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MV7JR|UxRTJwMECyOlIh|ryP NYPaUo54W0GQR1XS
LAN-6 M3q5[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M2rLW2lEPTB;Mj6wNVk3PiEQvF2= MX;TRW5ITVJ?
NCI-H510A M{nI[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIPKRVlKSzVyPUKuNFQ2ODJizszN M1fJbnNCVkeHUh?=
NCI-H1092 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MkjFTWM2OD1{LkC1NVI1KM7:TR?= M1fjdXNCVkeHUh?=
HT M4TXbmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnOzTWM2OD1{LkGwOFU1KM7:TR?= NWnHdI9KW0GQR1XS
RL95-2 NIK5fYtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MYLJR|UxRTJwMUG0PFIh|ryP NETpUpBUSU6JRWK=
NCI-H1355 M4e1WGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MkTiTWM2OD1{LkGxO|kzKM7:TR?= MnrXV2FPT0WU
NCI-H720 M4[1eGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MX\JR|UxRTJwMU[4O|Mh|ryP MnzzV2FPT0WU
NCI-H1522 MlXoS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXvJR|UxRTJwMkG3NlMh|ryP NV2yUWdoW0GQR1XS
LB373-MEL-D MoL5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NF3OflVKSzVyPUKuNlY6ODJizszN MnywV2FPT0WU
DG-75 NXfwSmZuT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFXUOllKSzVyPUKuNlcyPDhizszN MV7TRW5ITVJ?
ML-2 NIC1ToVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn\qTWM2OD1{LkOyPFU2KM7:TR?= NVvBWWhkW0GQR1XS
SF126 M3vUO2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MnW5TWM2OD1{LkOzNFk1KM7:TR?= MYjTRW5ITVJ?
MPP-89 MkfRS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M1PofWlEPTB;Mj6zN|E1PSEQvF2= MlnIV2FPT0WU
NCI-H345 MkP6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MmnoTWM2OD1{LkOzNlc4KM7:TR?= MmPPV2FPT0WU
LS-123 MojqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXXJR|UxRTJwM{S5N|Yh|ryP NYTGcnJ2W0GQR1XS
NB10 NU\0VZBHT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYewT4ZrUUN3ME2yMlQyODl{IN88US=> Ml62V2FPT0WU
CGTH-W-1 NELxZYxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYG4ZXNHUUN3ME2yMlQzOjZ5IN88US=> MVfTRW5ITVJ?
CP66-MEL MmOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M2\4TWlEPTB;Mj60O|c4KM7:TR?= NF\IO5VUSU6JRWK=
L-428 M1Kw[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVjJR|UxRTJwNEi1NlEh|ryP M2Lac3NCVkeHUh?=
DMS-79 NY[3NJk3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M3PpeWlEPTB;Mj61OFExOyEQvF2= NHLQdWhUSU6JRWK=
NCI-H1882 NV7RZ4t5T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M1SyO2lEPTB;Mj62O|U3OiEQvF2= NF;FO|hUSU6JRWK=
KGN MkPTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MWPJR|UxRTJwN{[4O|Yh|ryP MXnTRW5ITVJ?
EW-1 NInvbmZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MV;JR|UxRTJwN{ewPFMh|ryP Mmr2V2FPT0WU
U-266 MojwS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTyeJlZUUN3ME2yMlg1QDJ|IN88US=> M3nUZXNCVkeHUh?=
COLO-320-HSR M4GyXmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYLJR|UxRTJwOEW2OFEh|ryP MkXLV2FPT0WU
KMOE-2 M1HHVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MYnJR|UxRTJwOEe3NVEh|ryP M1vzXnNCVkeHUh?=
BB49-HNC M1ewb2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4frNWlEPTB;Mj65NlQ5KM7:TR?= MXXTRW5ITVJ?
GI-1 NIjHTpFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MVfJR|UxRTJwOUK5OVch|ryP NIX2Z4hUSU6JRWK=
NCI-H1304 M4nlNGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXrvNZgyUUN3ME2zMlAxPTFzIN88US=> NILwWlNUSU6JRWK=
NCI-H2227 M2DKZ2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MlniTWM2OD1|LkCyNFc6KM7:TR?= MUXTRW5ITVJ?
U-87-MG MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX\aOWJ5UUN3ME2zMlA{PTF|IN88US=> M1P6Z3NCVkeHUh?=
NCI-H747 NILjW5BIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFvwO29KSzVyPUOuNFUzODZizszN NHvmfY9USU6JRWK=
CTB-1 NGS1ZpRIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXPJR|UxRTNwMEWzO|Yh|ryP NGjzRWZUSU6JRWK=
RPMI-8226 NULrO2FVT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= Ml3QTWM2OD1|LkG0N|c5KM7:TR?= NITHNI9USU6JRWK=
NCI-H2141 NXrGN2NtT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NYS1T|BSUUN3ME2zMlE3PTZ4IN88US=> M1zTdHNCVkeHUh?=
IST-MES1 M3PmWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NIG1T3NKSzVyPUOuNVgzPzlizszN MW\TRW5ITVJ?
TE-5 MmTYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NWTPTopKUUN3ME2zMlIyOzR{IN88US=> MYTTRW5ITVJ?
UACC-257 NV\1dmZIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M2nhNGlEPTB;Mz60N|Y2QSEQvF2= NYW5VZJjW0GQR1XS
SK-N-FI Ml7PS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MY\JR|UxRTNwNEWyNlch|ryP NYXEWIZuW0GQR1XS
MFH-ino NFXE[3FIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYDSVVMyUUN3ME2zMlQ3PTh7IN88US=> MmTYV2FPT0WU
SF268 MWjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGHMSVJKSzVyPUOuOFgyPzRizszN NVrBSVdTW0GQR1XS
TE-12 MYPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NH3MOFNKSzVyPUOuOVE3QTlizszN NXvBNJVtW0GQR1XS
NB6 MljMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MUfJR|UxRTNwNUW1OlMh|ryP Mlv3V2FPT0WU
DJM-1 NFXTTmtIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHNT4VKSzVyPUOuOVk5QTlizszN MVTTRW5ITVJ?
MZ1-PC NXnrZ3Y2T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M164XmlEPTB;Mz62NVYzPCEQvF2= NX3obVFWW0GQR1XS
OCI-AML2 NYXNbIVIT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NFO5TYpKSzVyPUOuOlI3PzFizszN M1j3PXNCVkeHUh?=
NCI-H1155 NFvtZnZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jrPWlEPTB;Mz63NFk1PyEQvF2= NHPld3RUSU6JRWK=
RKO NGXYNZpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NXTSbGk1UUN3ME2zMlc4OTh7IN88US=> NEL6bFhUSU6JRWK=
ECC4 MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlPiTWM2OD1|Lkm3NVk2KM7:TR?= NHHMdlBUSU6JRWK=
BB65-RCC NUXu[GQ4T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NELSeYtKSzVyPUOuPVc2PDdizszN NHvtSFlUSU6JRWK=
EB-3 M4C5emdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NYL6cFlVUUN3ME2zMlk6PjN|IN88US=> NWq4WVBlW0GQR1XS
SHP-77 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2G1cGlEPTB;ND6wNFUzPCEQvF2= NHrk[FRUSU6JRWK=
NCI-H2196 NVXsZ2J6T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MW\JR|UxRTRwMEW2NlUh|ryP MoewV2FPT0WU
GI-ME-N NEDRUVhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3\kXGlEPTB;ND6wOlM6QSEQvF2= NHn0N|JUSU6JRWK=
MN-60 MULHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWTJR|UxRTRwMUC4O{DPxE1? NVvJZlJXW0GQR1XS
NCI-H1694 NGLzRmNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHnvbXJKSzVyPUSuNVM1ODVizszN MoXRV2FPT0WU
LU-65 NIDaWmVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYLrbHFkUUN3ME20MlE2OzN{IN88US=> M17rO3NCVkeHUh?=
NCI-H1436 NWfVZnVET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NILlcllKSzVyPUSuNVg{OzNizszN MlK1V2FPT0WU
KINGS-1 NWLufI5KT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUTJR|UxRTRwM{G0N|Ih|ryP M4LOO3NCVkeHUh?=
GT3TKB MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4PkWWlEPTB;ND6zN|I3QCEQvF2= NFHZPY9USU6JRWK=
Becker Mke5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4nWWGlEPTB;ND6zO|MyOiEQvF2= NWXrT5o4W0GQR1XS
HCC1187 MWrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFrmSW1KSzVyPUSuPFk3PTdizszN NXjFOYdpW0GQR1XS
D-502MG NISwNIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M33YXGlEPTB;NT6wNFQyPiEQvF2= MlzRV2FPT0WU
VA-ES-BJ MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M3vQV2lEPTB;NT6xN|c4QCEQvF2= NFzw[JJUSU6JRWK=
NB7 MUDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NGrtSItKSzVyPUWuNVQyOTJizszN MUnTRW5ITVJ?
SW962 MnLuS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NIrKUVdKSzVyPUWuN|g5OTRizszN MlPaV2FPT0WU
no-11 MUPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NXT1ZphYUUN3ME21Mlc3OzR|IN88US=> M1TIVHNCVkeHUh?=
KNS-81-FD NEHQfXNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NFG5W3lKSzVyPUWuPVA3QTRizszN MYPTRW5ITVJ?
COLO-684 NGPmdoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Ml70TWM2OD13Lkm5OFk1KM7:TR?= NWXvZpp1W0GQR1XS
D-263MG MlvJS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MoXBTWM2OD14LkC4PFk2KM7:TR?= NXjlU3VUW0GQR1XS
EW-24 MkjrS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NHHPV5ZKSzVyPU[uNlg2OSEQvF2= M4r6PHNCVkeHUh?=
TE-10 NWDZRpByT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MUjJR|UxRTZwNEK2NlMh|ryP NVjjcm9EW0GQR1XS
EKVX NGnnVo1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NYezeFBIUUN3ME22MlQ3OzJzIN88US=> M3\jZnNCVkeHUh?=
NCI-H1648 NGThW4hIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M3;0cWlEPTB;Nj62O|U2PyEQvF2= NWXVUHg5W0GQR1XS
LB771-HNC M3HFfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXy5TYx2UUN3ME22MlkzOzBzIN88US=> Ml72V2FPT0WU
SK-MEL-1 NFqwbWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4jjZ2lEPTB;OD6xN|E3PiEQvF2= NV;rVHN6W0GQR1XS
COLO-668 MmHnS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NFXzWWxKSzVyPUiuNlc4QDZizszN MlfLV2FPT0WU
EW-12 M4nkc2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MmjyTWM2OD16LkSwPFA{KM7:TR?= M1n4OHNCVkeHUh?=
A253 M3n6[2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NETZbFVKSzVyPUiuPFQ3PjFizszN MmHxV2FPT0WU
NCI-H2126 NF3Rc|NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4Lt[WlEPTB;OD64PVMyQSEQvF2= M4LZV3NCVkeHUh?=
Calu-6 MXfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M{\Y[GlEPTB;OD65PVA1OiEQvF2= MVrTRW5ITVJ?
NCI-H23 NWq2SlF{T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MX7JR|UxRTlwMUe3OFYh|ryP NYXZe5ZoW0GQR1XS
WSU-NHL MW\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M2C4dGlEPTB;OT63O|Q4QCEQvF2= M3PlenNCVkeHUh?=
MMAC-SF Mor6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? NELKWVFKSzVyPUmuPVc6ODRizszN NF64OlVUSU6JRWK=
SK-LMS-1 NWTJcoI1T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M13jUWlEPTB;MUCuNlg{PCEQvF2= NXTYfG5TW0GQR1XS
GCIY NFrPPVNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NUHyXZY4UUN3ME2xNE42QTJ2IN88US=> MVPTRW5ITVJ?
TE-15 NGCxNINIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NWnLenFPUUN3ME2xNU43ODB2IN88US=> MofLV2FPT0WU
EoL-1-cell M4TzcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NX3EXGRFUUN3ME2xNU44Pjh{IN88US=> M2LSTHNCVkeHUh?=
NCI-H2081 NYGzWFVTT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NXfOXGRvUUN3ME2xNU44Pzh4IN88US=> M2PFeXNCVkeHUh?=
EW-3 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NFG5RoFKSzVyPUGyMlI1PjNizszN M3zUU3NCVkeHUh?=
CAS-1 MkHzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MnH0TWM2OD1zMj6zOlMyKM7:TR?= Mom5V2FPT0WU
C2BBe1 MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MoHJTWM2OD1zMj62NVMyKM7:TR?= Ml;lV2FPT0WU
D-247MG NIrxd3pIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mk\NTWM2OD1zMj63PVUzKM7:TR?= MnLwV2FPT0WU
NCI-SNU-5 NHziSnBIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= Mn3lTWM2OD1zMj64NFE{KM7:TR?= MlXzV2FPT0WU
LS-1034 MVPHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? NX3R[Y1GUUN3ME2xOE4{QTd3IN88US=> MYPTRW5ITVJ?
EW-18 MYTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MmjuTWM2OD1zND60OFgh|ryP Mn\jV2FPT0WU
Raji MWXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MlHGTWM2OD1zND61NFQ6KM7:TR?= MXfTRW5ITVJ?
D-283MED NIDGWHVIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NIHqR|ZKSzVyPUG0MlYzPzFizszN MVvTRW5ITVJ?
MZ2-MEL NWDZTIplT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MnjhTWM2OD1zND65Olk3KM7:TR?= NGL5NVlUSU6JRWK=
NCI-SNU-16 MkHTS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? MXzJR|UxRTF3LkS2N|Mh|ryP Ml\4V2FPT0WU
P30-OHK MX\Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MUjJR|UxRTF5Lke4N|Eh|ryP MYLTRW5ITVJ?
RXF393 NFn4OVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MlS3TWM2OD1zOT6wNVg3KM7:TR?= MV;TRW5ITVJ?
NCI-H1395 M4\MSWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M4D1PGlEPTB;MkCuOlcxOyEQvF2= NILicodUSU6JRWK=
U-698-M NXftT21ET3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= M{nMcWlEPTB;MkCuO|A4PSEQvF2= MnPMV2FPT0WU
NCI-SNU-1 NYnwelQ3T3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= NH;xbYFKSzVyPUKwMlczOjNizszN NGHJZXFUSU6JRWK=
SW684 MXrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWLJR|UxRTJzLkG3NVYh|ryP NVjaVJZoW0GQR1XS
NCI-H716 MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? MWHJR|UxRTJzLkOxOVQh|ryP Mme5V2FPT0WU
JVM-2 NXr5OIlvT3Kxd4ToJGlvcGmkaYTpc44hSXO|YYm= MkGwTWM2OD1{MT60NVM{KM7:TR?= NGS1XmlUSU6JRWK=
NCI-H1581 NELiWYZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= M4XUfmlEPTB;MkKuOFE1QCEQvF2= MYfTRW5ITVJ?
CA46 MknIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl? M4m1eWlEPTB;M{GuOlk{PiEQvF2= MULTRW5ITVJ?
SNB75 NInVeWpIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MXLJR|UxRTN|Lk[1NFMh|ryP NXe3endFW0GQR1XS
KNS-42 MUTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M4\SPWlEPTB;M{WuPVYzPCEQvF2= NH74[VdUSU6JRWK=
TUR NIXaZWJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NHjzUotKSzVyPUO2MlA2OjFizszN MlXmV2FPT0WU
REH M4rvVGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 M{fW[2lEPTB;M{euPFIyOSEQvF2= MoL0V2FPT0WU
EW-22 M2i4[Gdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 MVPJR|UxRTR{LkK4PFUh|ryP NXXQ[2VIW0GQR1XS
NCI-H446 NE\reWhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= MkTiTWM2OD12Mj63PFU{KM7:TR?= M4TibnNCVkeHUh?=
ES3 MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>? M1LTZWlEPTB;NEOuNVM{QSEQvF2= Mnj5V2FPT0WU
EW-11 NEm0TWxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?= NGLYZ2dKSzVyPUS0MlgzOThizszN NFG5NYdUSU6JRWK=
RH-1 M2X2Rmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7 NXXUVJZrUUN3ME20O{42QDF{IN88US=> NHnpUpBUSU6JRWK=

他の多くの細胞株試験データをご覧になる場合はこちらをクリックして下さい

アッセイ
Methods Test Index PMID
Western blot
AcH3 / AcH4 / HDAC1 / HDAC2 / HDAC3; 

PubMed: 24203492     


HCT-15 or fresh primary NK cells were treated with entinostat for 24 h, and AcH3, AcH4, and HDAC1, 2, and 3 were detected by Western blotting. 

Cleaved PARP; 

PubMed: 19148581     


Induction of PARP cleavage in Daoy cells upon exposure to MS-275 was demonstrated by Western blot analyses using antibodies that recognize the cleaved 89 kDa PARP protein. Pan-Actin (45 kDa) was used as a loading control.

Caspase 8 ; 

PubMed: 19148581     


Cleavage of pro-Caspase-8 was demonstrated by Western blotting with extracts prepared from Daoy cells treated with 2.5 µM MS-275 for various time periods. Antibodies specific to human Caspase-8 or the loading control, pan-Actin were used to probe protein expression.

DR4 / DR5; 

PubMed: 19148581     


Western blotting to detect DR4 and DR5 expression upon treatment of Daoy cells with 2.5 µM MS-275 for 4, 8 and 24 h.

TopoIIα / TopoIIβ; 

PubMed: 21254166     


Upper panel, concentration-dependent effects of AR42, MS-275 and vorinostat on the expression of topoIIα versus topoIIβ after 48 h. Lower panel, time-dependent effect of 0.5 μM AR42 and 5 μM MS-275 on topoIIα versus topoIIβ expression in PLC-5 cells.

24203492 19148581 21254166
Immunofluorescence
phalloidin / snail; 

PubMed: 29855565     


(C) Effect of MS-275 treatment on Snail expression and localization. MCs (mesothelial cells) were treated with MS-275 (250 nM), or DMSO for 48 hr and then stimulated with TGFβ1 (2 ng/ml) for 24 h before processing for immunofluorescence with a monoclonal antibody against Snail. Cell nuclei are shown in blue (Hoechst 33342). Confocal images are shown from one representative experiment of three performed.

DR4 / DR5; 

PubMed: 19148581     


Flow Cytometry to measure cell surface expression of FAS, DR4 and DR5 using PE-labeled antibodies. Cells stained with isotype matched anti-human IgG antibodies served as controls.

H3K4Me3 / H3K9Me3; 

PubMed: 22468166     


Immunocytochemical analysis of the effects of AR42, SAHA, and MS-275 at the indicated concentrations on H3K4Me3 (upper panels) and H3K9Me3 (lower panels) after 24 h of treatment in LNCaP cells.

29855565 19148581 22468166
Growth inhibition assay
Cell proliferation; 

PubMed: 24203492     


(A) HCT-15 cells were cultured in indicated concentrations of entinostat for up to 72 h, and proliferation determined by MTT assay as indicated. (B) HCT-15, CCH-OS-D, COL and HOS cells were cultured in indicated concentrations of entinostat for 72 h, and viable cell number was determined using the Vi-cell assay and proliferation index calculated. (C) Freshly-isolated human NK cells were cultured in indicated concentrations of entinostat for up to 72 h, and viability was assessed by flow cytometry for 7-AAD uptake. *, P < 0.05, **; P ≤ 0.01; ***, P ≤ 0.001

Cell viability; 

PubMed: 28969017     


PANC-1, MIA PaCa-2, BxPC3, CFPAC-1, SUIT2 and SUIT2 Clone 1 cells were plated at a density of 3-5×103 per well in 96-well microtiter plates, allowed to adhere overnight and incubated for 72 hours in the presence of variable concentrations of entinostat (0-100μM). Cell viability was determined by XTT assays. The data presented are the mean values from triplicate wells from two independent experiments ±SE.

24203492 28969017
ELISA
GCP-2 / MCP-2 / MIF ; 

PubMed: 24241152     


MS-275 and SAHA suppressed the secretion of GCP-2, MCP-2 and MIF in E11 cells. (A) GCP suppression. (B) MCP-2 suppression. (C) MIF suppression. E11 cells were incubated with HDAC inhibitors at various concentrations for 1 h before they were stimulated by LPS. 24 h later, the secretion of GCP-2, MCP-2 and MIF were quantified by ELISA (n = 8). Bars show the mean and SD in (A–C).

24241152
体内試験 MS-275 exhibits great antitumor activity against human tumor xenografts except HCT-15 at 49 mg/kg. [1] MS-275 demonstrates promising therapeutic potential in both solid and hematologic malignancies, as well as regulation of physiologic and aberrant gene expression. [4] MS-275, combination with IL-2, has great antitumor activity to renal cell carcinoma xenograft model, which due to decreased T regulatory cells and increased splenocytes. [5]

お薦めの試験操作(参考用のみ)

キナーゼ試験:

[6]

- 合併

Standard HDAC Assays:

Rat liver enzyme is diluted 1:6 with HDAC buffer. Recombinant human HDACs are diluted 1:4 in HDAC buffer. For standard HDAC assays, 60 μL of HDAC buffer is mixed with 10 μL of diluted enzyme solution at 30 °C. The HDAC reaction is started by adding 30 μL substrate solution in HDAC buffer followed by 30 min of incubation at 30 °C. The reaction is stopped by adding 100 μL trypsin solutions (10 mg/ml trypsin in 50 mM Tris-HCl [pH 8.0], 100 mM NaCl, 2 μM TSA). After a 20 min incubation period at 30 °C, the release of AMC is monitored by measuring the fluorescence at 460 nm (λex = 390 nm). Fluorescence intensity is calibrated using free AMC. For standard time course experiments, 20 pmol of substrate is used in the initial 100 μL HDAC reaction. Km and Vmax values are determined by measuring the fluorescence AMC generated by enzymatic cleavage of 2–50 pmol of substrate. The experimental data are analyzed using a Hanes plot. The AMC signals are recorded against a blank with buffer and substrate but without the enzyme.
細胞試験:

[2]

- 合併
  • 細胞株: A2780, Calu-3, HL-60, K562, St-4, HT-29, KB-3-1, Capan-1, 4-1St and HCT-15 cells
  • 濃度: ~ 10 μM
  • 反応時間: 3 days
  • 実験の流れ:

    Cancer cells (5 × 103) are seeded into each well of 96-well plates and cultured with graded concentrations of MS-275 for 3 days. The cells are stained with 0.1 mg/mL neutral red for 1 hour in a CO2-incubator, and, after aspiration of the medium, OD540 of the neutral red solubilized with 50 μL of ethanol and 150 μL of 0.1 M Na2HPO4 is measured. The IC50 value is determined by plotting growth inhibition of the cells against the logarithm of the drug concentration.


    (参考用のみ)
動物試験:

[1]

- 合併
  • 動物モデル: A2780, HT-29, HTC-15, KB-3-1, 4-1St, St-4, Capan-1 and Calu-3 cells are injected subcutaneously into the flank of nude mice.
  • 投薬量: 12.3, 24.5 and 49 mg/kg
  • 投与方法: Administered orally once daily 5 days per week for 4 weeks
    (参考用のみ)

溶解度 (25°C)

体外 DMSO 75 mg/mL (199.25 mM)
Water Insoluble
Ethanol Insoluble
体内 左から(NMPから)右の順に溶剤を製品に加えます(文献ではなく、Selleckの実験によるデータ):
2% DMSO+30% PEG 300+ddH2O
混合させたのち直ちに使用することを推奨します。
10mg/mL

* 溶解度測定はSelleck技術部門によって行われており、その他文献に示されている溶解度と差異がある可能性がありますが、同一ロットの生産工程で起きる正常な現象ですからご安心ください。

化学情報

分子量 376.41
化学式

C21H20N4O3

CAS No. 209783-80-2
Storage powder
in solvent
別名 SNDX-275
Smiles NC1=CC=CC=C1NC(=O)C2=CC=C(CNC(=O)OCC3=CN=CC=C3)C=C2

投与溶媒組成計算器(クリア溶液)

ステップ1:実験データを入力してください。(実験操作によるロスを考慮し、動物数を1匹分多くして計算・調製することを推奨します)
投与量 mg/kg 動物平均体重 g 投与体積(動物毎) ul 動物数
ステップ2:投与溶媒の組成を入力してください。(ロット毎に適した溶解組成が異なる場合があります。詳細については弊社までお問い合わせください)
% DMSO % % Tween 80 % ddH2O
計算リセット

便利ツール

モル濃度計算器

モル濃度計算器

求めたい質量、体積または濃度を計算してください。

質量 (mg) = 濃度 (mM) x 体積 (mL) x 分子量 (g/mol)

モル濃度計算器方程式

  • 質量
    濃度
    体積
    分子量

*貯蔵液を準備するとき、常に、オンであるとわかる製品のバッチに特有の分子量を使って、を通してラベルとMSDS/COA(製品ページで利用可能な)。

希釈計算器

希釈計算器

貯蔵液を準備するために必要な希釈率を計算してください。Selleck希釈計算器は、以下の方程式に基づきます:

開始濃度 x 開始体積 = 最終濃度 x 最終体積

希釈の計算式

この方程式は、一般に略語を使われます:C1V1 = C2V2 ( 入力 出力 )

  • C1
    V1
    C2
    V2

常に貯蔵液を準備するとき、小びんラベルとMSDS/COA(オンラインで利用できる)で見つかる製品のバッチに特有の分子量を使ってください。

連続希釈計算器方程式

  • 連続希釈剤

  • 計算結果

  • C1=C0/X C1: LOG(C1):
    C2=C1/X C2: LOG(C2):
    C3=C2/X C3: LOG(C3):
    C4=C3/X C4: LOG(C4):
    C5=C4/X C5: LOG(C5):
    C6=C5/X C6: LOG(C6):
    C7=C6/X C7: LOG(C7):
    C8=C7/X C8: LOG(C8):
分子量計算器

分子量计算器

そのモル質量と元素組成を計算するために、合成物の化学式を入力してください:

総分子量:g/mol

チップス: 化学式は大文字と小文字の区別ができます。C10H16N2O2 c10h16n2o2

モル濃度計算器

質量 濃度 体積 分子量

臨床試験

NCT Number Recruitment interventions Conditions Sponsor/Collaborators Start Date Phases
NCT03829930 Recruiting Drug: Entinostat|Drug: Enzalutamide Prostate Adenocarcinoma George Washington University May 1 2019 Phase 1
NCT03765229 Recruiting Drug: Entinostat|Drug: Pembrolizumab Melanoma UNC Lineberger Comprehensive Cancer Center|Syndax Pharmaceuticals Inc. March 22 2019 Phase 2
NCT03473639 Recruiting Drug: Entinostat|Drug: Capecitabine Metastatic Breast Cancer|Breast Cancer University of Virginia|Syndax Pharmaceuticals January 29 2019 Phase 1
NCT03361800 Active not recruiting Drug: Entinostat Breast Cancer|Invasive Breast Cancer|ER-Negative PR-Negative HER2-Negative Breast Cancer UNC Lineberger Comprehensive Cancer Center|Syndax Pharmaceuticals|National Cancer Institute (NCI) November 28 2018 Early Phase 1
NCT03192111 Completed Drug: Entinostat Renal Impairment|Healthy Volunteer Syndax Pharmaceuticals July 27 2017 Phase 1

技術サポート

ストックの作り方、阻害剤の保管方法、細胞実験や動物実験の際に注意すべき点など、製品を取扱う時に問い合わせが多かった質問に対しては取扱説明書でお答えしています。

Handling Instructions

他に質問がある場合は、お気軽にお問い合わせください。

  • * 必須

よくある質問(FAQ)

  • 質問1:

    I would like to use Entinostat(Catalog No.S1053) for animal study. What is your recommendation for the solvent? What is the role of PEG 300 in this case? Can I use DMSO only and dilute it with PBS or HBSS?

  • 回答:

    2%DMSO/30%PEG/68%Water is recommended. PEG is an important polymer that helps with the solubility of hydrophobic drugs. If you use DMSO only and dilute it with PBS or HBSS, Entinostat will likely to precipitate out since it has very low solubility in water.

HDACシグナル伝達経路

HDAC Inhibitors with Unique Features

相関HDAC製品

Tags: Entinostat (MS-275)を買う | Entinostat (MS-275) ic50 | Entinostat (MS-275)供給者 | Entinostat (MS-275)を購入する | Entinostat (MS-275)費用 | Entinostat (MS-275)生産者 | オーダーEntinostat (MS-275) | Entinostat (MS-275)化学構造 | Entinostat (MS-275)分子量 | Entinostat (MS-275)代理店
×
細胞株 試験類型 濃度 培養時間 溶剤類型 活性叙述 PMID